CBG is a non-intoxicating cannabinoid, meaning it doesn’t produce the “highs” that are synonymous with THC. Because it is present in low levels (usually less than 1%) in most cannabis strains, CBG is considered a minor cannabinoid. Amazingly, however, THC and CBD start out as CBG—it’s the chemical parent of THC and CBD
Additionally, CBG can block the 5HT1A receptor while stimulating the TRPV1 and TRPV2 receptors. Blocking the 5HT1A receptor has been shown to improve learning and memory in rodents. Activation of the TRPV1 receptor, which is also seen in capsaicin, makes CBG a viable option for reducing pain. Activation of the TRPV2 receptor can reduce pain, but it also can regulate glucose levels.
CBG can also stimulate GPR55, and as a result, there can be a reduction in inflammatory pain and neuropathic pain. Furthermore, it can improve bone strength and bone mass.